<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diabetic kidney disease: Manifestations, evaluation, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diabetic kidney disease: Manifestations, evaluation, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diabetic kidney disease: Manifestations, evaluation, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy K Mottl, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katherine R Tuttle, MD, FASN, FACP, FNKF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4154619769"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in the United States and worldwide. While the gold standard for diagnosis of diabetic nephropathy is defined by histology of the kidney, the majority of patients do not undergo kidney biopsy, as they are presumed to have diabetic kidney disease based upon clinical history and laboratory evaluation. This clinical practice is based in part upon the desire to avoid an invasive procedure that may not alter treatment, as well as the notion that there is a uniform clinical disease presentation, a traditional belief based upon observational studies performed several decades ago. However, diabetic kidney disease is now known to be clinically and pathologically heterogeneous.</p><p>The clinical manifestations, evaluation, and diagnosis of diabetic kidney disease are reviewed in this topic. Other topics discuss the following issues:</p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology and pathogenesis of diabetic kidney disease (see  <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of diabetic kidney disease (see  <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of hypertension in patients with diabetes (see  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>)</p><p></p><p class="headingAnchor" id="H90600070"><span class="h1">TERMINOLOGY</span></p><p class="headingAnchor" id="H1174617514"><span class="h2">Diabetic kidney disease versus diabetic nephropathy</span><span class="headingEndMark"> — </span>The term "diabetic nephropathy" was historically defined by the clinical presence of albuminuria accompanied by retinopathy in patients with type 1 diabetes [<a href="#rid1">1</a>]. The presence of albuminuria was considered to be an early sign of classical diabetic glomerulopathy, which is characterized by glomerular basement membrane thickening, endothelial damage, mesangial expansion and nodules, and podocytes loss  (<a class="graphic graphic_picture graphicRef122305" href="/z/d/graphic/122305.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef122304" href="/z/d/graphic/122304.html" rel="external">picture 2</a>). Diabetic nephropathy was further subdivided into "overt nephropathy" by "macroalbuminuria" and "incipient nephropathy" by "microalbuminuria." These albuminuria distinctions were proposed to reflect a disease spectrum from mild to severe.</p><p>Since the original description of diabetic nephropathy, it has become clear that there are various forms of kidney disease attributable to diabetes, including nonclassical glomerular lesions and tubulointerstitial disease [<a href="#rid2">2</a>]. "Diabetic kidney disease" is a clinical diagnosis based upon the presence of albuminuria, decreased estimated glomerular filtration rate (eGFR), or both, in patients with diabetes. </p><p>Notably, diabetic kidney disease (DKD) does not indicate the specific pathological phenotype of kidney damage due to diabetes. Rather, the designation DKD (or "CKD in diabetes") is used to clarify that the underlying pathologic phenotype is unknown in most cases [<a href="#rid3">3</a>]. The likelihood that diabetic glomerulopathy is the underlying pathology of DKD varies widely depending upon the clinical circumstances. It is highly likely that diabetic glomerulopathy is the pathologic phenotype of diabetic kidney disease in type 1 diabetes of five or more years duration with albuminuria, but the frequency can vary widely in type 2 diabetes (where superimposed or de novo<em> </em>kidney disease due to other disorders is common). Only a kidney biopsy can confirm with certainty that diabetic kidney disease is due to diabetic glomerulopathy, but biopsies are infrequently performed for clinical purposes in such patients.</p><p class="headingAnchor" id="H2036150257"><span class="h2">Albuminuria and decreased glomerular filtration rate</span><span class="headingEndMark"> — </span>The albumin excretion rate can be estimated (using spot, or random, urine measurements of albumin and creatinine and calculating the albumin-to-creatinine ratio), or it can be measured (using a 24-hour urine collection). (See  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults", section on 'Detection and measurement of total urinary protein excretion'</a>.)</p><p>In clinical practice, GFR is estimated using creatinine-based equations (<a class="calc calc_professional" href="/z/d/html/15635.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/100996.html" rel="external">calculator 2</a>). (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function", section on 'Measurement of GFR with plasma clearance'</a>.)</p><p class="headingAnchor" id="H3989032271"><span class="h3">Moderately increased albuminuria (30 to 300 mg/g or mg/day)</span><span class="headingEndMark"> — </span>Previously termed "microalbuminuria," moderately increased albuminuria is defined as either an estimated or a measured urine albumin excretion between 30 and 300 mg/g creatinine or mg/day  (<a class="graphic graphic_table graphicRef56286" href="/z/d/graphic/56286.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults", section on 'Kidney damage'</a>.)</p><p>The change in terminology was intended to reflect more accurately the severity of moderately increased albuminuria (a range that is 10 to 100 times the upper limit of normal) and to avoid a common misperception that "microalbuminuria" signified the presence of "tiny albumin molecules."</p><p>Microalbuminuria was first described in patients with diabetes in the 1980s as the presence of small amounts of albuminuria that could be detected only with highly sensitive radioimmunoassays [<a href="#rid4">4,5</a>]. This was thought to be the earliest biomarker for underlying microvascular disease of the kidneys and was associated with later development of worsening albuminuria to the severely increased range (called "macroalbuminuria" at the time) and loss of GFR [<a href="#rid6">6,7</a>]. These early studies were performed in a small number of patients with mostly type 1 diabetes and at a time before hyperglycemia was established as a major modifiable risk factor for microvascular complications.</p><p>Any detectable albuminuria (even below the threshold for moderately increased albuminuria) forecasts a higher risk for future kidney disease and cardiovascular events in patients with diabetes; therefore, the presence of such low-grade albuminuria should not necessarily be considered "normal," particularly if persistent. (See  <a class="medical medical_review" href="/z/d/html/1545.html" rel="external">"Moderately increased albuminuria (microalbuminuria) and cardiovascular disease"</a>.)</p><p>Research protocol kidney biopsies performed in a cohort of 34 patients with type 2 diabetes and moderately increased albuminuria revealed that while one-third had typical underlying diabetic glomerulosclerosis, one-third had "atypical" findings more consistent with hypertensive nephrosclerosis, and another one-third had normal kidney histology [<a href="#rid8">8</a>]. The findings that a number of patients with diabetes with moderately increased albuminuria have normal kidney histology and can spontaneously regress have led some experts to regard moderately increased albuminuria as being of uncertain clinical relevance [<a href="#rid9">9</a>]. Other experts maintain that it still holds important implications for disease prognosis, not only for future kidney disease progression but also for cardiovascular complications, major comorbidities in patients with diabetic kidney disease [<a href="#rid10">10</a>]. In our view, these perspectives are not mutually exclusive, as moderately increased albuminuria can occur as the result of multiple physiologic and structural aberrations, each with distinct consequences, thus reflecting and reinforcing the extensive underlying heterogeneity of diabetic kidney disease.</p><p class="headingAnchor" id="H2998366771"><span class="h3">Severely increased albuminuria (&gt;300 mg/g or mg/day)</span><span class="headingEndMark"> — </span>Previously termed "macroalbuminuria," severely increased albuminuria is defined as either an estimated or a measured urine albumin excretion &gt;300 mg/g or mg/day  (<a class="graphic graphic_table graphicRef56286" href="/z/d/graphic/56286.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults", section on 'Kidney damage'</a>.)</p><p>Severely increased albuminuria forecasts an adverse prognosis. The risk for worsening GFR, end-stage kidney disease (ESKD), and cardiovascular events rises substantially with albuminuria levels that are severely increased [<a href="#rid11">11-13</a>], and levels above 1000 mg/g or mg/day are associated with even higher risk [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1820080855"><span class="h3">Decreased glomerular filtration rate</span><span class="headingEndMark"> — </span>Normal GFR is generally considered to be above 90 mL/min/1.73 m<sup>2</sup>, although there is substantial interindividual variability, and even levels in the 90 to 100 mL/min/1.73 m<sup>2 </sup>range may be pathologic for some individuals, especially if the GFR is on a declining trajectory.</p><p>In clinical practice, GFR is estimated using equations that are not sufficiently accurate except when the eGFR is &lt;60 mL/min/1.73 m<sup>2</sup>; therefore, the accepted definition of "decreased eGFR" is at this threshold, leaving individuals with eGFR 60 to 90 mL/min/1.73 m<sup>2</sup> unclassified regarding the clinical implication of their reduction in kidney function.</p><p>Measurement (rather than estimation) of GFR, which is rarely performed in clinical practice, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p class="headingAnchor" id="H2075380491"><span class="h1">NATURAL HISTORY</span></p><p class="headingAnchor" id="H1727486515"><span class="h2">Common misconceptions</span><span class="headingEndMark"> — </span>Clinical outcomes in diabetic kidney disease are quite variable, and there has been an evolution in what was once thought to be a single and unidirectional natural history. Historically, it was believed that patients began with either normal or elevated glomerular filtration rate (GFR; hyperfiltration), with the latter being most evident in type 1 diabetes in the setting of hyperglycemia, and that moderately increased albuminuria was the earliest clinically detectable biomarker of classical diabetic glomerulopathy  (<a class="graphic graphic_figure graphicRef122150" href="/z/d/graphic/122150.html" rel="external">figure 1</a>) [<a href="#rid15">15</a>]. A decline in estimated GFR (eGFR) to below 60 mL/min/1.73 m<sup>2</sup> was thought to occur <strong>after</strong> the development of moderately and then severely increased albuminuria.</p><p>However, contemporary studies have shown that albuminuria may regress, even from the severely increased range. In addition, decreased eGFR can occur and progress to advanced stages of chronic kidney disease (CKD) before the onset or without ever developing increased albuminuria [<a href="#rid16">16</a>]. The limitations of albuminuria as the "earliest" marker of diabetic kidney disease have led many experts to propose that "rapid eGFR decline" is of greater prognostic importance [<a href="#rid17">17</a>]. (See <a class="local">'Kidney function decline and end-stage kidney disease'</a> below.)</p><p class="headingAnchor" id="H1859928414"><span class="h2">Glomerular hyperfiltration and elevated GFR</span><span class="headingEndMark"> — </span>Some patients with type 1 or type 2 diabetes have a paradoxically high GFR early in their disease course (ie, "glomerular hyperfiltration"). Glomerular hyperfiltration is usually defined as GFR approximately 20 percent or more above that in age-matched, healthy controls without diabetes. In younger individuals, the usual threshold for hyperfiltration is considered 120 to 140 mL/min/1.73 m<sup>2</sup>, whereas in older adults it may be closer to 100 to 120 mL/min/1.73 m<sup>2</sup> [<a href="#rid18">18,19</a>]. The pathophysiology of glomerular hyperfiltration and its association with progression of diabetic kidney disease are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology"</a>.)</p><p>In studies of patients with diabetes that measured GFR, hyperfiltration was associated with greater risks of albuminuria progression and kidney function decline [<a href="#rid20">20-22</a>]. The kidney protective effects of renin angiotensin system (RAS) and sodium-glucose cotransporter 2 (SGLT2) inhibitors are thought to be mediated, at least in part, by reductions in glomerular hyperfiltration [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology"</a> and  <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a>.)</p><p class="headingAnchor" id="H3797003643"><span class="h2">Progression (or regression) of albuminuria</span><span class="headingEndMark"> — </span>In patients with diabetes, regression from moderately increased albuminuria to normoalbuminuria is common and, in patients with type 1 diabetes, may occur more frequently than progression to severely increased albuminuria [<a href="#rid25">25</a>]. Regression of moderately increased albuminuria also occurs in type 2 diabetes but less commonly than in type 1 diabetes [<a href="#rid26">26</a>].</p><p>In addition, regression of severely increased albuminuria to moderately increased albuminuria can occur in both type 1 and type 2 diabetes [<a href="#rid27">27-29</a>]. Remission of nephrotic-range proteinuria has also been reported [<a href="#rid30">30,31</a>].</p><p>The following studies illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 386 patients with type 1 diabetes and moderately increased albuminuria, regression to a normal level of albumin excretion occurred in 59 percent at six years, and progression to severely increased albuminuria occurred in 19 percent [<a href="#rid25">25</a>]. Factors favoring regression of albuminuria include better glycemic control, lower blood pressure, and lower total cholesterol and triglyceride levels. In a study of 397 patients with type 2 diabetes and moderately increased albuminuria, 22 percent had regression to normal levels of albumin excretion and 19 percent experienced progression to severely increased albuminuria [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a large study of patients with type 1 diabetes, severely increased albuminuria regressed to moderately increased albuminuria in 56 percent and to normoalbuminuria in 19 percent [<a href="#rid27">27,28</a>]. Smaller studies in type 2 diabetes have reported that 36 to 48 percent regressed from severely increased to moderately increased albuminuria and that 2 to 13 percent regressed to normoalbuminuria [<a href="#rid26">26,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two cohorts of patients with type 1 or type 2 diabetes and nephrotic range proteinuria, regression (defined as albuminuria persistent below 600 mg/day) was attained in 22 and 25 percent, respectively [<a href="#rid30">30,31</a>].</p><p></p><p>Regression of albuminuria is a favorable prognostic indicator. As an example, in a large meta-analysis of multiple cohorts and nearly 700,000 patients (including those with diabetes), a 30 percent regression in albuminuria was associated with a 22 percent reduction in the relative risk of ESKD [<a href="#rid32">32</a>]. In another study of patients with type 1 diabetes, the risk of rapid eGFR decline (defined as 3.3 percent or greater annual loss of eGFR over a period of up to 12 years) was similar in patients who always had normal albumin excretion and patients who had regressed to normal albumin excretion from moderately increased albuminuria [<a href="#rid33">33</a>]. Similar results have been reported in patients with type 2 diabetes who are able to achieve a remission, or even a 50 percent reduction, in albuminuria [<a href="#rid29">29</a>].</p><p>However, adverse prognostic consequences of any degree of albuminuria (even when it regresses to the normal range) are observed if patients are followed for a prolonged period. As an example, in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study, the risk of developing low eGFR (&lt;60 mL/min/1.73 m<sup>2</sup>) among those who had regression of albuminuria was fourfold higher at 30 years compared with patients who had persistent normoalbuminuria [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1116718946"><span class="h2">Kidney function decline and end-stage kidney disease</span><span class="headingEndMark"> — </span>Defining the natural history of kidney function decline in patients with diabetic kidney disease is difficult for a variety of reasons [<a href="#rid25">25,34-37</a>]: interindividual variability, which is due in part to sociodemographic and clinical risk factors; temporal trends in the use of effective therapies to slow progression (improvements in glycemic and blood pressure control and use of RAS and SGLT2 inhibitors); nonlinear trajectories in eGFR decline; few studies with longitudinal direct measurements (rather than estimates) of GFR; and relatively low correlation between long-term changes in eGFR compared with measured GFR. In addition, studies of the natural history of GFR decline frequently involve clinical trial participants who typically have a better prognosis than those not enrolled in trials. Therefore, these studies may provide a lower-range estimate of GFR decline compared with the general population.</p><p>The accuracy and precision of longitudinal changes in eGFR are imperfect and not necessarily equivalent to longitudinal changes in measured (or "true") GFR. In addition, the accuracy of eGFR equations to estimate GFR slope over time may be worse in diabetic compared with nondiabetic kidney disease [<a href="#rid35">35,37</a>]. While changes in eGFR may not reflect changes in measured GFR, eGFR changes over time nevertheless have prognostic value for end-stage kidney disease (ESKD) and mortality [<a href="#rid38">38</a>].</p><p>The average annual rate of decline in eGFR due to age-related senescence of the kidney in otherwise healthy individuals is 0.5 to 1 mL/min/1.73 m<sup>2</sup> per year [<a href="#rid39">39</a>]. In diabetes, the rate of eGFR decline varies, but it is typically more rapid (&gt;3 mL/min/1.73 m<sup>2</sup> per year), particularly in patients with a long duration of diabetes (&gt;10 years), severely increased albuminuria, or low baseline eGFR (&lt;60 mL/min/1.73 m<sup>2</sup>). The following studies illustrate the range of findings [<a href="#rid35">35,36,40-42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 997 patients with type 1 diabetes in the DCCT/EDIC study who had an average duration of diabetes of 5.5 years at the initial evaluation, the median decrease in eGFR at approximately three years was 3 mL/min/1.73 m<sup>2</sup> [<a href="#rid35">35</a>]. However, variability was high, and one-quarter of the population had a three-year decline of 14 mL/min/1.73 m<sup>2</sup> or greater, while some patients had an overall increase in GFR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a long-term observational study of 410 people with newly diagnosed type 2 diabetes (mean age 59 years, eGFR 84 mL/min/1.73 m<sup>2</sup>, 13 percent with moderately increased albuminuria), 11 percent had an eGFR decline &gt;3 mL/min/1.73 m<sup>2</sup> per year and 27 percent had a decline between 1 and 2.9 mL/min/1.73 m<sup>2</sup> per year. Independent predictors of a more rapid eGFR decline included baseline retinopathy and increased albuminuria [<a href="#rid43">43</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another cohort of 1908 people with type 2 diabetes and chronic kidney disease followed over a median of 6.3 years, albuminuria status at baseline was associated with rapidity of kidney function decline. In those with albuminuria &lt;30, 30 to 299, 300 to 1000, or &gt;1,000 mg/24 hours at baseline, annual eGFR decline was -0.2, -1.4, -2.7, and -4.7 mL/min/1.73 m<sup>2</sup>, respectively [<a href="#rid44">44</a>].</p><p></p><p>The risk of progression to ESKD depends upon many factors, including the type of diabetes (type 1 versus type 2), access to care, the use of treatments to slow progression, and other risk factors:</p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based study of Australian individuals from 2002 to 2013, the incidence of ESKD was 19 per 10,000 person-years in those with type 1 diabetes and 10 per 10,000 person-years in those with type 2 diabetes. In addition, the incidence rate was higher for Indigenous versus non-Indigenous people and for males versus females [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 932 patients with type 1 diabetes in the United States diagnosed between 1965 and 1980, 20- and 40-year cumulative incidence of ESKD were 5.5 and 27 percent, respectively [<a href="#rid46">46</a>]. By contrast, in a cohort of 7871 patients with type 1 diabetes from Norway diagnosed between 1971 and 2012, the 20- and 40-year rates of ESKD were 0.7 and 5.3 percent, respectively [<a href="#rid47">47</a>]. This substantial difference is multifactorial but is likely due at least in part to temporal trends in glycemic and blood pressure control and use of RAS inhibitors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term ESKD rates for type 2 diabetes in the United States also vary. Data from two large cohorts reported incidence rates of 2.5 to 6 cases per 1000 person-years; however, this follow-up time does not represent diabetes duration, which was different at the baseline visit for both studies [<a href="#rid48">48,49</a>]. In addition, many participants in these studies had CKD at baseline. Incidence rates were 0.9, 2.4, 10.5, and 97.8 cases of ESKD per 1000 person-years for patients whose baseline eGFR was &gt;60, 45 to 60, 30 to 45, and &lt;30 mL/min/1.73 m<sup>2</sup>, respectively.</p><p></p><p>Although the incidence of ESKD attributed to diabetes has declined negligibly over the past 10 years [<a href="#rid50">50-52</a>], the prevalence of ESKD attributed to diabetes has steadily risen to nearly 50 percent of all cases in the United States. As an attributable cause of ESKD, diabetes is most common and steadily increasing due to the rapidly expanding number of people living with diabetes worldwide [<a href="#rid50">50,53</a>]. Notably, in both diabetic and nondiabetic kidney diseases, African Americans have a higher risk for ESKD than other racial or ethnic groups [<a href="#rid50">50</a>] due to a combination of disparities in socioeconomic status, access to care, and possibly genetic predisposition [<a href="#rid54">54-56</a>]. (See  <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology"</a>.)</p><p>There are also other populations with exceedingly high rates of diabetic ESKD, such as Aboriginal people in Canada and Northern Australia, wherein the lifetime risk for ESKD approaches 50 percent [<a href="#rid57">57,58</a>].</p><p class="headingAnchor" id="H2186478755"><span class="h3">Nonalbuminuric diabetic kidney disease</span><span class="headingEndMark"> — </span>Reduced eGFR in patients with diabetes can occur in the absence of albuminuria [<a href="#rid59">59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with type 1 diabetes and reduced eGFR (&lt;60 mL/min/1.73 m<sup>2</sup>), 7 to 24 percent are nonalbuminuric (urine albumin &lt;30 mg/day or &lt;30 mg/g of creatinine) [<a href="#rid27">27,60,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with type 2 diabetes and reduced eGFR, 39 to 52 percent are nonalbuminuric [<a href="#rid62">62-65</a>].</p><p></p><p>The prevalence of nonalbuminuric CKD rises with age in parallel with albuminuric CKD and is less frequent among diabetic versus nondiabetic cohorts [<a href="#rid66">66,67</a>], indicating that it is probably not simply due to age-related senescence of the kidney [<a href="#rid63">63</a>]. The prevalence of nonalbuminuric CKD is consistently higher in women than in men [<a href="#rid63">63,66-68</a>]. Other factors associated with the presence of nonalbuminuric diabetic kidney disease include RAS inhibition [<a href="#rid62">62,63</a>], hypertension [<a href="#rid64">64,68</a>], dyslipidemia [<a href="#rid64">64,68</a>], and smoking [<a href="#rid64">64,68</a>].</p><p>The prevalence of diabetic retinopathy is lower in individuals with nonalbuminuric compared with albuminuric CKD (10 to 43 versus 22 to 62 percent, respectively) [<a href="#rid60">60,63,67,69,70</a>]. By contrast, the prevalence of macrovascular disease is similar between nonalbuminuric and albuminuric CKD groups in most [<a href="#rid60">60,70</a>], but not all [<a href="#rid63">63</a>], studies.</p><p>The lower prevalence of retinopathy in nonalbuminuric compared with albuminuric CKD could reflect mechanisms of nonalbuminuric disease apart from microangiopathy, such as macrovascular disease [<a href="#rid62">62,68,71</a>]. However, one study that investigated macrovascular disease as a pathogenic factor in nonalbuminuric CKD by performing renal duplex imaging of the interlobar renal arteries found that resistive index did not differ by albuminuria status [<a href="#rid72">72</a>]. Studies in which protocol biopsies were obtained in patients with normal levels of albumin excretion have revealed various findings, including classic diabetic glomerulopathy, predominantly vascular and tubulointerstitial disease, and nonspecific findings [<a href="#rid73">73,74</a>]. (See <a class="local">'Pathology'</a> below.)</p><p>Progression of diabetic kidney disease appears to be slower in patients with nonalbuminuric disease, regardless of diabetes type [<a href="#rid27">27,60,75</a>]. In the DCCT/EDIC study of patients with type 1 diabetes, the rate of eGFR decline was 1.2 percent per year for those with normoalbuminuria, 1.7 percent per year for those with moderately increased albuminuria, and 5.7 percent per year for those with severely increased albuminuria [<a href="#rid27">27</a>]. Of the 20 people who reached ESKD, all had severely increased albuminuria at the time their eGFR fell below 60 mL/min/1.73 m<sup>2</sup>. Similarly, in a Finnish cohort of patients with type 1 diabetes, ESKD developed in 63 percent of those with baseline moderately or severely increased albuminuria but only in 1.3 percent of those with nonalbuminuric CKD [<a href="#rid60">60</a>].</p><p>Despite having a slower rate of eGFR decline, patients with nonalbuminuric CKD are at high risk for eventual progression if followed over a sufficiently long period of time. In the United States, the crude incidence rate of kidney failure for nonalbuminuric CKD is approximately 7.4 cases per 1000 person-years [<a href="#rid44">44</a>]; in addition, cross-sectional studies have shown that, among patients with diabetes with stage 4 or 5 CKD (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>), 27 to 30 percent were normoalbuminuric [<a href="#rid63">63,68</a>].</p><p class="headingAnchor" id="H4221840453"><span class="h2">Cardiovascular events and death</span><span class="headingEndMark"> — </span>Although progression to advanced CKD and ESKD is a major concern, cardiovascular events and death occur more frequently than the need for kidney replacement therapy, particularly in patients with a urine albumin excretion &lt;1000 mg/g of creatinine or an eGFR above 45 mL/min/1.73 m<sup>2</sup> [<a href="#rid13">13,14,76-79</a>]. Higher levels of albuminuria (even those below 30 mg/g) and lower levels of eGFR independently and additively increase the risk for cardiovascular events and death [<a href="#rid11">11,78,80-82</a>]. In patients at high cardiovascular risk, the incidence of cardiovascular events is approximately 2.5-fold higher for every 10-fold increase in urine albumin excretion and approximately twofold higher for every halving of eGFR [<a href="#rid78">78,82</a>].</p><p class="headingAnchor" id="H2076930028"><span class="h1">MANIFESTATIONS AND DIAGNOSIS</span></p><p class="headingAnchor" id="H2259174629"><span class="h2">Manifestations and case detection</span><span class="headingEndMark"> — </span>The most common clinical abnormalities of diabetic kidney disease are persistently elevated urine albumin excretion (ie, moderately increased or severely increased albuminuria) and/or persistently decreased estimated glomerular filtration rate (eGFR). In severe cases, albuminuria levels can be above the nephrotic threshold of 3.5 g per 24 hours, resulting in the nephrotic syndrome [<a href="#rid28">28,83</a>].</p><p>These manifestations are typically asymptomatic and are therefore usually detected through routine, periodic testing. We agree with guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) organizations that patients with diabetes should undergo annual testing for kidney complications using serum creatinine-based eGFR and urine tests for abnormal levels of albumin excretion [<a href="#rid84">84,85</a>]. Abnormal results should be confirmed by repeat testing over a period of three to six months.</p><p>Type 1 diabetes generally presents more conspicuously than type 2 diabetes, which can be asymptomatic for years prior to diagnosis. As a result, testing is recommended to commence in patients with type 1 diabetes five years after diagnosis. In patients with type 2 diabetes, testing for kidney disease is recommended to be undertaken at the time of diagnosis.</p><p>Urine albumin excretion can be estimated using a spot urine sample and the albumin-to-creatinine ratio, which is the method most often used in clinical practice, or measured using the historical approach of a timed (24-hour or other) urine collection. At least two of three urine collections obtained over a three- to six-month period should reveal elevated levels of albumin before the presence of albuminuria can be established [<a href="#rid84">84,86</a>]. The basis for this recommendation is that there is significant intraindividual variability in daily urine albumin excretion [<a href="#rid87">87</a>]; in addition, various conditions (eg, uncontrolled hyperglycemia, exercise, urinary tract infection, heart failure exacerbations, high dietary protein intake) can induce transient albuminuria in the absence of abnormal kidney pathology [<a href="#rid88">88</a>].</p><p>Qualitative urine albumin dipsticks, which will turn "positive" in the presence of abnormally high albumin concentrations, are not sufficient to determine albuminuria progression or the response to treatment.</p><p>GFR can be estimated using several different creatinine-based equations; however, the Chronic Kidney Disease Epidemiology (CKD-EPI) [<a href="#rid89">89</a>] and Modification of Diet in Renal Disease (MDRD) [<a href="#rid90">90</a>] equations are most commonly used (<a class="calc calc_professional" href="/z/d/html/15635.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/100996.html" rel="external">calculator 2</a>). The advantages and disadvantages of these equations are presented separately. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function", section on 'Measurement of GFR with plasma clearance'</a>.)</p><p>However, these equations were developed in primarily nondiabetic populations and their validity and precision may be reduced in patients with diabetic kidney disease [<a href="#rid36">36,91</a>], uncontrolled hyperglycemia [<a href="#rid92">92</a>], and overweight/obesity [<a href="#rid93">93</a>].</p><p>The urine sediment in diabetic kidney disease is usually bland, but patients with severely increased albuminuria may have microscopic hematuria [<a href="#rid94">94,95</a>], and those with nephrotic-range proteinuria often have oval fat bodies or lipid droplets. Dysmorphic red blood cells and red blood cell casts are uncommon in patients with diabetic kidney disease and are therefore suggestive of nondiabetic kidney disease and should prompt a search for glomerulonephritis [<a href="#rid96">96</a>].</p><p>The prevalence of hematuria was assessed in a large Taiwanese cohort of 1958 patients with diabetes, most of whom had severely increased albuminuria and eGFR &lt;60 mL/min/1.73 m<sup>2</sup> [<a href="#rid95">95</a>]. Microscopic hematuria was present in 48 percent (15 percent had moderate hematuria, defined as ≥5 red blood cells per high-powered field). Kidney biopsy was performed in 111 patients, 61 of whom were diagnosed with classic diabetic glomerulopathy alone. The prevalence of any microscopic hematuria was somewhat lower among those with classic diabetic glomerulopathy compared with those who had nondiabetic kidney disease (59 versus 84 percent), as was the prevalence of moderate hematuria (26 versus 50 percent).</p><p>In a meta-analysis of 35 studies and more than 4000 patients with diabetes who underwent urinalysis and kidney biopsy, the sensitivity and specificity of microscopic hematuria for detecting nondiabetic kidney disease were relatively poor (42 and 72 percent, respectively), suggesting that microscopic hematuria alone is insufficient to distinguish diabetic and nondiabetic kidney disease [<a href="#rid94">94</a>]. However, the presence of dysmorphic red blood cells in the urine, while insensitive, was highly specific (94 percent) for nondiabetic kidney disease. Thus, patients with dysmorphic hematuria are likely to have nondiabetic kidney disease, either alone or in combination with diabetic kidney disease.</p><p class="headingAnchor" id="H2332866574"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Diabetic kidney disease is typically a clinical (or presumptive) diagnosis. (See <a class="local">'Clinical diagnosis of diabetic kidney disease'</a> below.)</p><p>Kidney biopsy is rarely performed to confirm the diagnosis. Rather, a kidney biopsy is most commonly used when an alternative diagnosis (eg, glomerulonephritis or primary nephrotic syndrome) is suspected. (See <a class="local">'Confirmatory biopsy if diagnosis is uncertain'</a> below.)</p><p class="headingAnchor" id="H2922740412"><span class="h3">Clinical diagnosis of diabetic kidney disease</span><span class="headingEndMark"> — </span>A clinical diagnosis of diabetic kidney disease can be made if the following conditions are satisfied:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent albuminuria and/or persistent decreased GFR</strong> – As noted above albuminuria is defined as a urine albumin excretion ≥30 mg/day (if measured by a timed collection) or ≥30 mg/g (if using a spot urine albumin-to-creatinine ratio to estimate excretion). Decreased GFR is defined as an eGFR &lt;60 mL/min/1.73 m<sup>2</sup> using a creatinine-based formula. Persistence of these abnormalities for at least three months should be confirmed because transient abnormalities, which can be induced by a variety of unrelated disorders, are common. (See <a class="local">'Albuminuria and decreased glomerular filtration rate'</a> above.)</p><p></p><p class="bulletIndent1">Albuminuria <strong>is not</strong> required to make a clinical diagnosis of diabetic kidney disease. A substantial minority of patients with diabetes and decreased eGFR have &lt;30 mg/g of albuminuria, and such patients commonly have histopathologic findings consistent with diabetic kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long duration of diabetes or established diabetic retinopathy</strong> – In patients with type 1 diabetes, five years is a sufficiently long duration.</p><p></p><p class="bulletIndent1">By contrast, in patients with type 2 diabetes, diabetic kidney disease can be present at the time of diagnosis. Patients with type 2 diabetes are often asymptomatic and, if not receiving annual monitoring of fasting glucose and glycated hemoglobin, can have diabetes for many years before it is discovered. Even those patients who undergo routine monitoring, and therefore have their diabetes diagnosed shortly after onset, have been exposed to prediabetes and hyperglycemia for a prolonged period, and prediabetes is associated with albuminuria or decreased eGFR in a substantial proportion of patients [<a href="#rid97">97</a>]. Thus, at the time of diagnosis, patients with type 2 diabetes are considered to have had the disorder for a duration sufficiently long to produce kidney disease.</p><p></p><p class="bulletIndent1">In patients with evidence of kidney disease, the presence of proliferative diabetic retinopathy correlates with pathologic features of diabetic kidney disease. Thus, a clinical diagnosis of diabetic kidney disease can be made in patients with established retinopathy, even if the duration of diabetes is short.</p><p></p><p class="bulletIndent1">Persistently poor glycemic control and poor blood pressure control in these patients further increase the likelihood that kidney disease is due to diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>A judgment that alternate etiologies are unlikely</strong> – Making a presumptive diagnosis of diabetic kidney disease should be avoided if there are features present that suggest an alternative explanation for the kidney disease. Thus, a presumptive clinical diagnosis of diabetic kidney disease should <strong>not</strong> be made if any of the following apply:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severely elevated albuminuria (ie, ≥300 mg/day or mg/g) within five years of onset of type 1 diabetes, or severely elevated albuminuria for many years prior to the onset of type 2 diabetes (if the date of onset is known).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Red blood cell casts, dysmorphic red blood cells, or white blood cell casts in the urine sediment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of another systemic disease that is commonly associated with kidney disease (eg, systemic lupus erythematosus)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A sudden increase albuminuria or a rapid decline in eGFR; in particular, a sustained rise in albuminuria of greater than 5- to 10-fold that occurs over a period of less than one to two years and an eGFR decline greater than 5 mL/min/1.73 m<sup>2</sup> per year are atypical in diabetic kidney disease and should therefore raise suspicion for an alternative etiology.</p><p></p><p>The diagnosis of diabetic kidney disease is clinical and based upon the presence of albuminuria or reduced eGFR. In general, the cause of chronic kidney disease (CKD) is presumed to be diabetic kidney disease based upon the presence of longstanding diabetes (at least five years duration in the case of type 1 diabetes), particularly if retinopathy is present [<a href="#rid86">86</a>]. Kidney biopsy studies have suggested that the absence of retinopathy and presence of severe (particularly proliferative) retinopathy are strong predictors for nondiabetic and diabetic kidney pathology, respectively [<a href="#rid98">98-101</a>].</p><p>The history of glycemic and blood pressure control should also be taken into account as factors predisposing to diabetic kidney disease, although historic levels may be difficult to ascertain in patients with longstanding diabetes [<a href="#rid102">102,103</a>].</p><p>When diagnosing diabetic kidney disease, the magnitude of albuminuria and rapidity of eGFR decline should be considered in relation to other clinical factors, and alternative etiologies should be suspected if the pattern of albuminuria and eGFR decline are atypical.</p><p>Severely elevated albuminuria prior to five years of type 1 diabetes duration is rare, and this degree of albuminuria is not likely to occur until closer to 10 years' duration if glycemic control has been somewhat reasonable (eg, glycated hemoglobin [HbA1c] &lt;9 percent) [<a href="#rid28">28</a>]. Nephrotic-range proteinuria is atypical in diabetes of less than 10 to 15 years' duration [<a href="#rid28">28</a>].</p><p>Sudden increases in the magnitude of albuminuria are uncommon in diabetic kidney disease. Although data are scarce, it is the opinion of the authors that a sustained rise in albuminuria of greater than 5- to 10-fold that occurs rapidly (over a period of less than one to two years) is unusual in diabetic kidney disease.</p><p>Sudden decreases in eGFR would also be reason to consider other causes of kidney disease. As described above, the rate of eGFR decline is quite variable in diabetes and can be as rapid as 5 mL/min/1.73 m<sup>2</sup> per year. Deterioration more rapid than this rate should raise concern about other etiologies of kidney disease, particularly when accompanied by other atypical changes in albuminuria magnitude or the presence of dysmorphic hematuria.</p><p>Microscopic hematuria is common in patients with diabetic kidney disease and is most often identified in patients with severe albuminuria (albumin-to-creatinine ratio &gt;1000 mg/g) and low eGFR [<a href="#rid95">95</a>]. However, red blood cell casts or dysmorphic red cells are uncommon and should raise the possibility of a glomerulonephritis [<a href="#rid96">96</a>]. Alternative diagnoses such as tubulointerstitial diseases should also be suspected if white blood cell casts are present.</p><p>The sensitivity of albuminuria and low eGFR for detection of early diabetic kidney disease is poor [<a href="#rid104">104</a>]. The limitations preclude early detection and prognostication of diabetic kidney disease and pose a challenge for the development of new therapeutics to prevent progression of early-stage disease. As a result, various circulating and urinary biomarkers are being developed for use as diagnostic and prognostic tools [<a href="#rid105">105-118</a>] but are not yet in clinical use.</p><p class="headingAnchor" id="H4202648361"><span class="h3">Confirmatory biopsy if diagnosis is uncertain</span><span class="headingEndMark"> — </span>In patients with diabetes with severe albuminuria or decreased eGFR, a kidney biopsy should usually be performed if nondiabetic kidney disease is suspected; reasons to suspect an alternate etiology are presented above. (See <a class="local">'Clinical diagnosis of diabetic kidney disease'</a> above.)</p><p>The histologic findings consistent with diabetic nephropathy are discussed below. (See <a class="local">'Pathology'</a> below.)</p><p>While the primary purpose of kidney biopsy is considered to be diagnostic, it also offers useful prognostic information. The glomerular disease class and degree of interstitial fibrosis yield information regarding time to end-stage kidney disease (ESKD) [<a href="#rid119">119,120</a>]. Acute tubular necrosis is common among patients with diabetes and may or may not be reversible [<a href="#rid101">101,121</a>].</p><p>In many regions, the health care culture is to avoid kidney biopsy in patients with diabetes, but there is concern that many patients with nondiabetic kidney disease go undiagnosed [<a href="#rid101">101,122</a>]. One study, for example, examined health centers that had a biopsy policy for patients with diabetes that was "restricted" (ie, a kidney biopsy was only performed if a nondiabetic pathology was suspected based upon clinical findings) and centers that had an "unrestricted" policy (kidney biopsy was performed if there was severe albuminuria, low eGFR, or hematuria) [<a href="#rid123">123</a>]. Even when biopsies were restricted to patients in whom an alternate diagnosis was suspected, 29 percent had diabetic kidney disease alone (with no other diagnosis). Conversely, when biopsies were unrestricted (and performed among patients with suspected diabetic kidney disease), 33 percent had an alternate diagnosis that might have otherwise been missed if a biopsy was not performed.</p><p>As another example, in a single-center cohort of 611 patients who underwent kidney biopsy, one-fourth were performed in patients with diabetes [<a href="#rid121">121</a>]. Of these, one-third revealed classic diabetic glomerulopathy alone, one-third showed diabetic glomerulopathy plus nondiabetic kidney disease, and one-third showed nondiabetic kidney disease alone. The most common nondiabetic kidney diseases identified were acute tubular necrosis (28 percent), immune-mediated glomerular diseases (25 percent), hypertensive nephrosclerosis (18 percent), and focal segmental glomerulosclerosis (18 percent; nearly all of which was due to secondary causes). In the United States, the majority of kidney biopsies performed in people with diabetes occur at late stages of disease, when median eGFR is 20 to 30 mL/min/1.73 m<sup>2</sup> and median albuminuria is 3000 to 5000 mg/g [<a href="#rid120">120,121</a>]. This means that patients with diabetes with nondiabetic kidney disease are often not diagnosed until their disease is severely advanced.</p><p class="headingAnchor" id="H287701718"><span class="h4">Pathology</span><span class="headingEndMark"> — </span>Patients with type 1 diabetes predominantly develop classical diabetic glomerulopathy, whereas patients with type 2 diabetes, particularly those without albuminuria, may have a myriad of pathologic findings in the kidney.</p><p>The initial abnormality of classical diabetic glomerulopathy is thickening of the glomerular basement membrane, which can occur as soon as two years following diagnosis of type 1 diabetes  (<a class="graphic graphic_picture graphicRef122305" href="/z/d/graphic/122305.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef122304" href="/z/d/graphic/122304.html" rel="external">picture 2</a>) [<a href="#rid124">124</a>]. Other major diabetic glomerular changes include mesangial expansion, which can be diffuse or nodular (often termed "Kimmelstiel-Wilson nodules"), podocyte injury, and glomerular sclerosis  (<a class="graphic graphic_picture graphicRef122305" href="/z/d/graphic/122305.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef122304" href="/z/d/graphic/122304.html" rel="external">picture 2</a>) [<a href="#rid125">125,126</a>]. The mesangial expansion and glomerulosclerosis do not always develop in parallel, suggesting that they may have different underlying pathogenesis [<a href="#rid62">62</a>]. Arteriolar hyalinosis and arteriosclerosis of larger vessels are common [<a href="#rid127">127</a>], likely representing the combined effect of hyperglycemia and hypertension  (<a class="graphic graphic_picture graphicRef122306" href="/z/d/graphic/122306.html" rel="external">picture 3</a>). Tubulointerstitial fibrosis usually occurs after the initial glomerular lesions and is a final pathway-mediating progression to advanced CKD and ESKD. As above, pathologic abnormalities in type 2 diabetes are more heterogeneous than in type 1 diabetes, with a large proportion of patients having dominant vascular and tubulointerstitial disease more than glomerular involvement [<a href="#rid8">8,74,127</a>].</p><p>Patients with diabetes who have kidney disease may also have other histopathologic findings, especially in those with type 2 diabetes and normal levels of urine albumin excretion (see <a class="local">'Nonalbuminuric diabetic kidney disease'</a> above). Research biopsies performed in patients with type 1 diabetes and albuminuria &lt;30 mg/day found changes consistent with classic diabetic glomerulopathy (glomerular basement membrane thickening and mesangial expansion), particularly among those with GFR &lt;90 mL/min/1.73 m<sup>2</sup> [<a href="#rid73">73</a>]. Conversely, research biopsies from eight individuals with type 2 diabetes and nonalbuminuric CKD revealed classical diabetic glomerulopathy with predominant mesangial expansion and glomerular basement membrane thickening in three patients, predominant vascular and tubulointerstitial disease in three patients, and mild, nonspecific changes in two patients [<a href="#rid74">74</a>]. This is in contrast to five of six patients with type 2 diabetes, CKD, and moderately increased albuminuria who were observed to have typical diabetic glomerulopathy.</p><p class="headingAnchor" id="H764268816"><span class="h4">Renal Pathology Society classification</span><span class="headingEndMark"> — </span>A classification of type 1 and type 2 diabetic kidney disease was developed by the research committee of the Renal Pathology Society [<a href="#rid128">128</a>], which provides a systematic and uniform approach to classify pathology of the diabetic kidney and also promotes the study of pathogenesis and prognosis of disease. Scores are assigned to all three kidney compartments: the glomeruli; vasculature; and interstitium:</p><p class="bulletIndent1"><span class="glyph">●</span>Class I – Isolated glomerular basement membrane thickening. Basement membranes are greater than 430 nm in males and 395 nm in females over the age of nine years. There is no evidence of mesangial expansion, increased mesangial matrix, or global glomerulosclerosis involving &gt;50 percent of glomeruli.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class II – Mild (Class IIa) or severe (Class IIb) mesangial expansion. A lesion is considered severe if areas of expansion larger than the mean area of a capillary lumen are present in &gt;25 percent of the total mesangium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class III – At least one Kimmelstiel-Wilson lesion (nodular intercapillary glomerulosclerosis) is observed on biopsy, and there is &lt;50 percent global glomerulosclerosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class IV – Advanced diabetic glomerulosclerosis. There is &gt;50 percent global glomerulosclerosis that is attributable to diabetic nephropathy.</p><p></p><p>The clinical and prognostic significance of these glomerular classes has been evaluated in several retrospective cohort studies. Progression to ESKD is less common in classes I and IIa and more rapid in class IV. However, it is less clear whether or not class III (nodular glomerulosclerosis) carries a worse prognosis than class IIb (diffuse glomerulosclerosis) [<a href="#rid119">119,120</a>]. A limitation of this classification is that potentially important pathologic lesions are not included, such as the presence of focal and segmental sclerosis, mesangiolysis, capillary aneurysms, exudative lesions, and extracapillary hypercellularity [<a href="#rid120">120,129</a>].</p><p class="headingAnchor" id="H3702108858"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>In patients with diabetes, albuminuria and reduced eGFR can result from nondiabetic kidney disease. Reasons to perform a kidney biopsy to detect nondiabetic kidney disease are presented above. (See <a class="local">'Clinical diagnosis of diabetic kidney disease'</a> above and <a class="local">'Confirmatory biopsy if diagnosis is uncertain'</a> above.)</p><p>The differential diagnosis of albuminuria and reduced eGFR is large. A detailed discussion is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p>Conditions other than diabetes can cause nodular glomerulosclerosis, most of which are identified by characteristic findings on immunofluorescence or electron microscopy [<a href="#rid126">126</a>]. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Dysproteinemias such as amyloidosis and monoclonal immunoglobulin deposition diseases (MIDD), mostly kappa light chain deposition disease (see  <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">"Renal amyloidosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Organized glomerular deposition diseases, fibrillary and immunotactoid glomerulonephritis, fibronectin glomerulopathy, and collagen III glomerulopathy (see  <a class="medical medical_review" href="/z/d/html/3115.html" rel="external">"Glomerular diseases due to nonamyloid fibrillar deposits"</a> and  <a class="medical medical_review" href="/z/d/html/3072.html" rel="external">"Glomerulopathy with fibronectin deposits"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic hypoxic or ischemic conditions [<a href="#rid130">130</a>], such as cyanotic congenital heart disease, Takayasu arteritis with renal artery stenosis, or cystic fibrosis [<a href="#rid131">131</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic membranoproliferative glomerulonephritis (type I) (see  <a class="medical medical_review" href="/z/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic nodular glomerulosclerosis, which is often associated with smoking and hypertension [<a href="#rid132">132</a>]</p><p></p><p class="headingAnchor" id="H2098055152"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/140971.html" rel="external">"Society guideline links: Diabetic kidney disease"</a>.)</p><p class="headingAnchor" id="H2694187984"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>"Diabetic nephropathy" is characterized pathologically by glomerular basement membrane thickening, endothelial damage, mesangial expansion and nodules, and podocyte loss. However, it has become clear that there are various forms of kidney disease due to diabetes including nonclassical glomerular lesions as well as tubulointerstitial disease. Thus, the term "diabetic kidney disease" is used to reflect the presence of albuminuria, decreased estimated glomerular filtration rate (eGFR), or both, but it is not intended to indicate a specific kidney disease phenotype in a patient with diabetes. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical outcomes in diabetic kidney disease are widely variable, and there has been an evolution in what was once thought to be a single and unidirectional natural history. Historically, it was believed that patients began with either normal or elevated GFR (ie, "hyperfiltration") and that moderately increased albuminuria was the earliest clinically detectable biomarker of classical diabetic glomerulopathy  (<a class="graphic graphic_figure graphicRef122150" href="/z/d/graphic/122150.html" rel="external">figure 1</a>). A decline in eGFR to below 60 mL/min/1.73 m<sup>2</sup> was thought to occur <strong>after</strong> the development of moderately and then severely increased albuminuria. However, contemporary studies have shown that albuminuria may regress, even from the severely increased range. In addition, decreased eGFR can occur and progress to advanced stages of chronic kidney disease (CKD) before the onset or without the development of albuminuria. Although progression to advanced CKD and end-stage kidney disease (ESKD) is a major concern, cardiovascular events and death occur more frequently than the need for kidney replacement therapy. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common clinical abnormalities of diabetic kidney disease are persistently elevated urine albumin excretion (ie, moderately increased or severely increased albuminuria) and/or persistently decreased eGFR. In severe cases, albuminuria levels can be above the nephrotic syndrome threshold of 3.5 g per 24 hours. Early manifestations are typically asymptomatic and are therefore usually detected through routine, periodic testing. Abnormal results should be confirmed by repeat testing over a period of at least three months. (See <a class="local">'Manifestations and case detection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The urine sediment in diabetic kidney disease is usually bland, but patients with severely increased albuminuria may have microscopic hematuria, and those with nephrotic-range proteinuria often have oval fat bodies or lipid droplets in the sediment. Dysmorphic red blood cells and red blood cell casts are uncommon in patients with diabetic kidney disease and therefore suggest nondiabetic kidney disease, particularly glomerulonephritis. (See <a class="local">'Manifestations and case detection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetic kidney disease is typically a clinical (or presumptive) diagnosis. Kidney biopsy is rarely performed to confirm the diagnosis in clinical practice. Rather, a kidney biopsy is most commonly used when an alternative diagnosis (eg, glomerulonephritis or primary nephrotic syndrome) is suspected.</p><p></p><p class="bulletIndent1">A clinical diagnosis of diabetic kidney disease can be made if the following conditions are satisfied (see <a class="local">'Clinical diagnosis of diabetic kidney disease'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent albuminuria and/or persistent decreased GFR. Albuminuria <strong>is not</strong> required to make a clinical diagnosis of diabetic kidney disease. A substantial minority of patients with diabetes and a decreased eGFR have &lt;30 mg/g of albuminuria, and such patients commonly have histopathologic findings consistent with diabetic kidney disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Long duration of diabetes or established diabetic retinopathy. In patients with type 1 diabetes, five years is a sufficiently long duration. By contrast, in patients with type 2 diabetes, diabetic kidney disease can be present at the time that diabetes is diagnosed. In patients with evidence of kidney disease, the presence of proliferative diabetic retinopathy correlates with pathologic features of diabetic kidney disease. Thus, a clinical diagnosis of diabetic kidney disease can be made in patients with established retinopathy, even if the duration of diabetes is short.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A judgment that alternate etiologies are unlikely. Making a presumptive diagnosis of diabetic kidney disease should be avoided if there are features present that suggest an alternative explanation for the kidney disease. Thus, a presumptive clinical diagnosis of diabetic kidney disease should <strong>not</strong> be made if any of the following conditions apply:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Severely elevated albuminuria (ie, ≥300 mg/day or mg/g) within five years of onset of type 1 diabetes or severely elevated albuminuria for many years prior the onset of type 2 diabetes (if the date of onset is known).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Red blood cell casts, dysmorphic red blood cells, or white blood cell casts in the urine sediment.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Presence of another systemic disease that is commonly associated with kidney disease (eg, systemic lupus erythematosus).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A sudden increase in albuminuria or a rapid decline in eGFR; in particular, a sustained rise in albuminuria of greater than 5- to 10-fold that occurs over a period of less than one to two years and an eGFR decline greater than 5 mL/min/1.73 m<sup>2</sup> per year are atypical in diabetic kidney disease and should raise suspicion for an alternative etiology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with diabetes with severe albuminuria or decreased eGFR, a kidney biopsy should usually be performed if nondiabetic kidney disease is suspected. (See <a class="local">'Confirmatory biopsy if diagnosis is uncertain'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conditions other than diabetes can cause nodular glomerulosclerosis, most of which are identified by characteristic findings on immunofluorescence or electron microscopy [<a href="#rid126">126</a>]. These include dysproteinemias, organized glomerular deposition disease, chronic hypoxic conditions, chronic membranoproliferative glomerulonephritis, and idiopathic nodular glomerulosclerosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Olivarius Nde F, Andreasen AH, Keiding N, Mogensen CE. Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark. Diabetologia 1993; 36:1007.</a></li><li><a class="nounderline abstract_t">Di Vincenzo A, Bettini S, Russo L, et al. Renal structure in type 2 diabetes: facts and misconceptions. J Nephrol 2020; 33:901.</a></li><li><a class="nounderline abstract_t">Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Ann Intern Med 2021; 174:385.</a></li><li><a class="nounderline abstract_t">Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311:89.</a></li><li><a class="nounderline abstract_t">Parving HH, Oxenbøll B, Svendsen PA, et al. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) 1982; 100:550.</a></li><li><a class="nounderline abstract_t">Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1:1430.</a></li><li><a class="nounderline abstract_t">Nelson RG, Knowler WC, Pettitt DJ, et al. Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 1991; 151:1761.</a></li><li><a class="nounderline abstract_t">Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39:1569.</a></li><li><a class="nounderline abstract_t">MacIsaac RJ, Ekinci EI, Jerums G. 'Progressive diabetic nephropathy. How useful is microalbuminuria?: contra'. Kidney Int 2014; 86:50.</a></li><li><a class="nounderline abstract_t">Roscioni SS, Lambers Heerspink HJ, de Zeeuw D. Microalbuminuria: target for renoprotective therapy PRO. Kidney Int 2014; 86:40.</a></li><li><a class="nounderline abstract_t">de Boer IH, Gao X, Cleary PA, et al. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clin J Am Soc Nephrol 2016; 11:1969.</a></li><li><a class="nounderline abstract_t">Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996; 335:1636.</a></li><li><a class="nounderline abstract_t">Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225.</a></li><li><a class="nounderline abstract_t">Packham DK, Alves TP, Dwyer JP, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 2012; 59:75.</a></li><li><a class="nounderline abstract_t">Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32 Suppl 2:64.</a></li><li><a class="nounderline abstract_t">Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 2014; 37:226.</a></li><li><a class="nounderline abstract_t">Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care 2015; 38:954.</a></li><li><a class="nounderline abstract_t">Vora JP, Dolben J, Dean JD, et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 1992; 41:829.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Bruton JL. Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 1992; 42:167.</a></li><li><a class="nounderline abstract_t">Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J Am Soc Nephrol 2017; 28:1023.</a></li><li><a class="nounderline abstract_t">Magee GM, Bilous RW, Cardwell CR, et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009; 52:691.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012; 35:2061.</a></li><li><a class="nounderline abstract_t">Ibrahim HN, Rosenberg ME, Hostetter TH. Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review. Semin Nephrol 1997; 17:431.</a></li><li><a class="nounderline abstract_t">Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018; 94:26.</a></li><li><a class="nounderline abstract_t">Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348:2285.</a></li><li><a class="nounderline abstract_t">Bentata Y, Karimi I, Benabdellah N, et al. Albuminuria in type 2 diabetes mellitus: from remission to progression. Ren Fail 2016; 38:481.</a></li><li><a class="nounderline abstract_t">Molitch ME, Steffes M, Sun W, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33:1536.</a></li><li><a class="nounderline abstract_t">de Boer IH, Afkarian M, Rue TC, et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2014; 25:2342.</a></li><li><a class="nounderline abstract_t">Yokoyama H, Araki S, Honjo J, et al. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care 2013; 36:3227.</a></li><li><a class="nounderline abstract_t">Hovind P, Rossing P, Tarnow L, et al. Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 2001; 24:1972.</a></li><li><a class="nounderline abstract_t">Rossing K, Christensen PK, Hovind P, Parving HH. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia 2005; 48:2241.</a></li><li><a class="nounderline abstract_t">Coresh J, Heerspink HJL, Sang Y, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol 2019; 7:115.</a></li><li><a class="nounderline abstract_t">Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18:1353.</a></li><li><a class="nounderline abstract_t">Weldegiorgis M, de Zeeuw D, Li L, et al. Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. Am J Kidney Dis 2018; 71:91.</a></li><li><a class="nounderline abstract_t">de Boer IH, Sun W, Cleary PA, et al. Longitudinal changes in estimated and measured GFR in type 1 diabetes. J Am Soc Nephrol 2014; 25:810.</a></li><li><a class="nounderline abstract_t">Gaspari F, Ruggenenti P, Porrini E, et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013; 84:164.</a></li><li><a class="nounderline abstract_t">Padala S, Tighiouart H, Inker LA, et al. Accuracy of a GFR estimating equation over time in people with a wide range of kidney function. Am J Kidney Dis 2012; 60:217.</a></li><li><a class="nounderline abstract_t">Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311:2518.</a></li><li><a class="nounderline abstract_t">Denic A, Glassock RJ, Rule AD. Structural and Functional Changes With the Aging Kidney. Adv Chronic Kidney Dis 2016; 23:19.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6:605.</a></li><li><a class="nounderline abstract_t">Rossing K, Christensen PK, Hovind P, et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66:1596.</a></li><li><a class="nounderline abstract_t">Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380:2295.</a></li><li><a class="nounderline abstract_t">Zoppini G, Trombetta M, Pastore I, et al. Glomerular filtration rate decline in T2DM following diagnosis. The Verona newly diagnosed diabetes study-12. Diabetes Res Clin Pract 2021; 175:108778.</a></li><li><a class="nounderline abstract_t">Koye DN, Magliano DJ, Reid CM, et al. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 2018; 72:653.</a></li><li><a class="nounderline abstract_t">Koye DN, Magliano DJ, Reid CM, et al. Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013. Am J Kidney Dis 2019; 73:300.</a></li><li><a class="nounderline abstract_t">Costacou T, Orchard TJ. Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset. Diabetes Care 2018; 41:426.</a></li><li><a class="nounderline abstract_t">Gagnum V, Saeed M, Stene LC, et al. Low Incidence of End-Stage Renal Disease in Childhood-Onset Type 1 Diabetes Followed for Up to 42 Years. Diabetes Care 2018; 41:420.</a></li><li><a class="nounderline abstract_t">Bash LD, Astor BC, Coresh J. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010; 55:31.</a></li><li><a class="nounderline abstract_t">Amin AP, Whaley-Connell AT, Li S, et al. The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2013; 61:S12.</a></li><li class="breakAll">United States Renal Data System. USRDS 2018 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, editor,  National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2018. https://www.usrds.org/2014/view/.</li><li><a class="nounderline abstract_t">Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014; 370:1514.</a></li><li><a class="nounderline abstract_t">Gregg EW, Hora I, Benoit SR. Resurgence in Diabetes-Related Complications. JAMA 2019; 321:1867.</a></li><li class="breakAll">IDF Diabetes Atlas, 8, International Diabetes Federation (Ed), Brussels 2017.</li><li><a class="nounderline abstract_t">Lipworth L, Mumma MT, Cavanaugh KL, et al. Incidence and predictors of end stage renal disease among low-income blacks and whites. PLoS One 2012; 7:e48407.</a></li><li><a class="nounderline abstract_t">McDonough CW, Palmer ND, Hicks PJ, et al. A genome-wide association study for diabetic nephropathy genes in African Americans. Kidney Int 2011; 79:563.</a></li><li><a class="nounderline abstract_t">Wang Y, Katzmarzyk PT, Horswell R, et al. Racial disparities in diabetic complications in an underinsured population. J Clin Endocrinol Metab 2012; 97:4446.</a></li><li><a class="nounderline abstract_t">Wang Z, Hoy WE. Diabetes and lifetime risk of ESRD in high-risk remote-dwelling Australian Aboriginal people: a 20-year cohort study. Am J Kidney Dis 2013; 62:845.</a></li><li><a class="nounderline abstract_t">Dart AB, Sellers EA, Martens PJ, et al. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care 2012; 35:1265.</a></li><li><a class="nounderline abstract_t">Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289:3273.</a></li><li><a class="nounderline abstract_t">Thorn LM, Gordin D, Harjutsalo V, et al. The Presence and Consequence of Nonalbuminuric Chronic Kidney Disease in Patients With Type 1 Diabetes. Diabetes Care 2015; 38:2128.</a></li><li><a class="nounderline abstract_t">Costacou T, Ellis D, Fried L, Orchard TJ. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007; 50:721.</a></li><li><a class="nounderline abstract_t">MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27:195.</a></li><li><a class="nounderline abstract_t">Penno G, Solini A, Bonora E, et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011; 29:1802.</a></li><li><a class="nounderline abstract_t">Yokoyama H, Sone H, Oishi M, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009; 24:1212.</a></li><li><a class="nounderline abstract_t">Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55:1832.</a></li><li><a class="nounderline abstract_t">Mottl AK, Kwon KS, Mauer M, et al. Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications 2013; 27:123.</a></li><li><a class="nounderline abstract_t">Thomas MC, Macisaac RJ, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 2009; 32:1497.</a></li><li><a class="nounderline abstract_t">Dwyer JP, Parving HH, Hunsicker LG, et al. Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal Med 2012; 2:1.</a></li><li><a class="nounderline abstract_t">Bash LD, Selvin E, Steffes M, et al. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2008; 168:2440.</a></li><li><a class="nounderline abstract_t">Ito H, Takeuchi Y, Ishida H, et al. High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant 2010; 25:1161.</a></li><li><a class="nounderline abstract_t">Porrini E, Ruggenenti P, Mogensen CE, et al. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol 2015; 3:382.</a></li><li><a class="nounderline abstract_t">MacIsaac RJ, Panagiotopoulos S, McNeil KJ, et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 2006; 29:1560.</a></li><li><a class="nounderline abstract_t">Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52:1036.</a></li><li><a class="nounderline abstract_t">Ekinci EI, Jerums G, Skene A, et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care 2013; 36:3620.</a></li><li><a class="nounderline abstract_t">Buyadaa O, Magliano DJ, Salim A, et al. Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2020; 43:122.</a></li><li><a class="nounderline abstract_t">Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013; 24:302.</a></li><li><a class="nounderline abstract_t">Afkarian M, Katz R, Bansal N, et al. Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study. Clin J Am Soc Nephrol 2016; 11:1384.</a></li><li><a class="nounderline abstract_t">Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380:1662.</a></li><li><a class="nounderline abstract_t">Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010; 53:2312.</a></li><li><a class="nounderline abstract_t">Scirica BM, Mosenzon O, Bhatt DL, et al. Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. JAMA Cardiol 2018; 3:155.</a></li><li><a class="nounderline abstract_t">Cea Soriano L, Johansson S, Stefansson B, Rodríguez LA. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovasc Diabetol 2015; 14:38.</a></li><li><a class="nounderline abstract_t">Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20:1813.</a></li><li><a class="nounderline abstract_t">O'Shaughnessy MM, Hogan SL, Poulton CJ, et al. Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986-2015. Clin J Am Soc Nephrol 2017; 12:614.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42:S124.</a></li><li><a class="nounderline abstract_t">Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72:247.</a></li><li><a class="nounderline abstract_t">KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49:S12.</a></li><li><a class="nounderline abstract_t">McHardy KC, Gann ME, Ross IS, Pearson DW. A simple approach to screening for microalbuminuria in a type 1 (insulin-dependent) diabetic population. Ann Clin Biochem 1991; 28 ( Pt 5):450.</a></li><li><a class="nounderline abstract_t">Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18:572.</a></li><li><a class="nounderline abstract_t">Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604.</a></li><li><a class="nounderline abstract_t">Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461.</a></li><li><a class="nounderline abstract_t">MacIsaac RJ, Ekinci EI, Premaratne E, et al. The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function. BMC Nephrol 2015; 16:198.</a></li><li><a class="nounderline abstract_t">Cherney DZ, Sochett EB, Dekker MG, Perkins BA. Ability of cystatin C to detect acute changes in glomerular filtration rate provoked by hyperglycaemia in uncomplicated Type 1 diabetes. Diabet Med 2010; 27:1358.</a></li><li><a class="nounderline abstract_t">Lemoine S, Guebre-Egziabher F, Sens F, et al. Accuracy of GFR estimation in obese patients. Clin J Am Soc Nephrol 2014; 9:720.</a></li><li><a class="nounderline abstract_t">Jiang S, Wang Y, Zhang Z, et al. Accuracy of hematuria for predicting non-diabetic renal disease in patients with diabetes and kidney disease: A systematic review and meta-analysis. Diabetes Res Clin Pract 2018; 143:288.</a></li><li><a class="nounderline abstract_t">Lin HY, Niu SW, Kuo IC, et al. Hematuria and Renal Outcomes in Patients With Diabetic Chronic KidneyDisease. Am J Med Sci 2018; 356:268.</a></li><li><a class="nounderline abstract_t">O'Neill WM Jr, Wallin JD, Walker PD. Hematuria and red cell casts in typical diabetic nephropathy. Am J Med 1983; 74:389.</a></li><li><a class="nounderline abstract_t">Ali MK, Bullard KM, Saydah S, et al. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014. Lancet Diabetes Endocrinol 2018; 6:392.</a></li><li><a class="nounderline abstract_t">Dong Z, Wang Y, Qiu Q, et al. Clinical predictors differentiating non-diabetic renal diseases from diabetic nephropathy in a large population of type 2 diabetes patients. Diabetes Res Clin Pract 2016; 121:112.</a></li><li><a class="nounderline abstract_t">Li L, Zhang X, Li Z, et al. Renal pathological implications in type 2 diabetes mellitus patients with renal involvement. J Diabetes Complications 2017; 31:114.</a></li><li><a class="nounderline abstract_t">Tan J, Zwi LJ, Collins JF, et al. Presentation, pathology and prognosis of renal disease in type 2 diabetes. BMJ Open Diabetes Res Care 2017; 5:e000412.</a></li><li><a class="nounderline abstract_t">Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrol Dial Transplant 2017; 32:97.</a></li><li><a class="nounderline abstract_t">Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580.</a></li><li><a class="nounderline abstract_t">Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59:2298.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis 2014; 64:510.</a></li><li><a class="nounderline abstract_t">Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Diabetologia 2018; 61:996.</a></li><li><a class="nounderline abstract_t">Pena MJ, de Zeeuw D, Mischak H, et al. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. Nephrol Dial Transplant 2015; 30 Suppl 4:iv86.</a></li><li><a class="nounderline abstract_t">Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant 2005; 20:2601.</a></li><li><a class="nounderline abstract_t">Alicic RZ, Johnson EJ, Tuttle KR. Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Adv Chronic Kidney Dis 2018; 25:181.</a></li><li><a class="nounderline abstract_t">Navarro JF, Mora-Fernández C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006; 17:441.</a></li><li><a class="nounderline abstract_t">Gohda T, Niewczas MA, Ficociello LH, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012; 23:516.</a></li><li><a class="nounderline abstract_t">Coca SG, Nadkarni GN, Huang Y, et al. Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. J Am Soc Nephrol 2017; 28:2786.</a></li><li><a class="nounderline abstract_t">Bhatraju PK, Zelnick LR, Shlipak M, et al. Association of Soluble TNFR-1 Concentrations with Long-Term Decline in Kidney Function: The Multi-Ethnic Study of Atherosclerosis. J Am Soc Nephrol 2018; 29:2713.</a></li><li><a class="nounderline abstract_t">Niewczas MA, Gohda T, Skupien J, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23:507.</a></li><li><a class="nounderline abstract_t">Pavkov ME, Nelson RG, Knowler WC, et al. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 2015; 87:812.</a></li><li><a class="nounderline abstract_t">Argilés Á, Siwy J, Duranton F, et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013; 8:e62837.</a></li><li><a class="nounderline abstract_t">Lindhardt M, Persson F, Zürbig P, et al. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial Transplant 2017; 32:1866.</a></li><li><a class="nounderline abstract_t">Zürbig P, Mischak H, Menne J, Haller H. CKD273 Enables Efficient Prediction of Diabetic Nephropathy in Nonalbuminuric Patients. Diabetes Care 2019; 42:e4.</a></li><li><a class="nounderline abstract_t">Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, et al. Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. Sci Rep 2018; 8:15940.</a></li><li><a class="nounderline abstract_t">An Y, Xu F, Le W, et al. Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant 2015; 30:257.</a></li><li><a class="nounderline abstract_t">Mottl AK, Gasim A, Schober FP, et al. Segmental Sclerosis and Extracapillary Hypercellularity Predict Diabetic ESRD. J Am Soc Nephrol 2018; 29:694.</a></li><li><a class="nounderline abstract_t">Sharma SG, Bomback AS, Radhakrishnan J, et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 2013; 8:1718.</a></li><li><a class="nounderline abstract_t">Caramori ML. Should all patients with diabetes have a kidney biopsy? Nephrol Dial Transplant 2017; 32:3.</a></li><li><a class="nounderline abstract_t">Mazzucco G, Bertani T, Fortunato M, et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis 2002; 39:713.</a></li><li><a class="nounderline abstract_t">Osterby R. Morphometric studies of the peripheral glomerular basement membrane in early juvenile diabetes. I. Development of initial basement membrane thickening. Diabetologia 1972; 8:84.</a></li><li><a class="nounderline abstract_t">Adler S. Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int 2004; 66:2095.</a></li><li><a class="nounderline abstract_t">Najafian B, Fogo AB, Lusco MA, Alpers CE. AJKD Atlas of Renal Pathology: diabetic nephropathy. Am J Kidney Dis 2015; 66:e37.</a></li><li><a class="nounderline abstract_t">Rodríguez-Rodríguez R, Hojs R, Trevisani F, et al. The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease. Kidney Int Rep 2021; 6:2392.</a></li><li><a class="nounderline abstract_t">Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21:556.</a></li><li><a class="nounderline abstract_t">Furuichi K, Yuzawa Y, Shimizu M, et al. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Dial Transplant 2018; 33:138.</a></li><li><a class="nounderline abstract_t">Herzenberg AM, Holden JK, Singh S, Magil AB. Idiopathic nodular glomerulosclerosis. Am J Kidney Dis 1999; 34:560.</a></li><li><a class="nounderline abstract_t">Westall GP, Binder J, Kotsimbos T, et al. Nodular glomerulosclerosis in cystic fibrosis mimics diabetic nephropathy. Nephron Clin Pract 2004; 96:c70.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Lin J, Valeri AM, et al. Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol 2002; 33:826.</a></li></ol></div><div id="topicVersionRevision">Topic 119881 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8243848" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32656750" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Renal structure in type 2 diabetes: facts and misconceptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33166222" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6738599" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Predicting diabetic nephropathy in insulin-dependent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6812342" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6123720" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1888242" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960844" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Patterns of renal injury in NIDDM patients with microalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24717301" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 'Progressive diabetic nephropathy. How useful is microalbuminuria?: contra'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24759154" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Microalbuminuria: target for renoprotective therapy PRO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27797889" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8929360" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472787" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22051245" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6400670" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23939543" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25998286" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1513105" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1635346" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143897" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19198800" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22773704" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Glomerular hyperfiltration and renal disease progression in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9316211" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29735306" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788992" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Regression of microalbuminuria in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26822401" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Albuminuria in type 2 diabetes mellitus: from remission to progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413518" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24925722" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Renal outcomes in patients with type 1 diabetes and macroalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23780946" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11679467" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Remission of nephrotic-range albuminuria in type 1 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170513" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30635225" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329575" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29153995" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309189" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Longitudinal changes in estimated and measured GFR in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23447062" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The GFR and GFR decline cannot be accurately estimated in type 2 diabetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22495467" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Accuracy of a GFR estimating equation over time in people with a wide range of kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24892770" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26709059" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Structural and Functional Changes With the Aging Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29910024" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15458456" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Progression of nephropathy in type 2 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30990260" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33766697" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Glomerular filtration rate decline in T2DM following diagnosis. The Verona newly diagnosed diabetes study-12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29784612" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30579709" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28931542" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025877" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Low Incidence of End-Stage Renal Disease in Childhood-Onset Type 1 Diabetes Followed for Up to 42 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19932544" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23507266" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23507266" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24738668" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Changes in diabetes-related complications in the United States, 1990-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985875" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Resurgence in Diabetes-Related Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985875" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Resurgence in Diabetes-Related Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23110237" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Incidence and predictors of end stage renal disease among low-income blacks and whites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150874" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A genome-wide association study for diabetic nephropathy genes in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22977274" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Racial disparities in diabetic complications in an underinsured population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849064" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diabetes and lifetime risk of ESRD in high-risk remote-dwelling Australian Aboriginal people: a 20-year cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22432116" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : High burden of kidney disease in youth-onset type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12824208" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26310691" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The Presence and Consequence of Nonalbuminuric Chronic Kidney Disease in Patients With Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954285" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693989" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Nonalbuminuric renal insufficiency in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21738053" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical significance of nonalbuminuric renal impairment in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984626" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731850" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182925" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Normoalbuminuric diabetic kidney disease in the U.S. population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470839" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22493597" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064828" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892756" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25943757" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801579" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663477" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23835690" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31796570" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362314" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Kidney disease and increased mortality risk in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27340284" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23013602" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20665208" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29214305" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25909295" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19443635" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28325866" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559237" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17568785" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276798" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1958047" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A simple approach to screening for microalbuminuria in a type 1 (insulin-dependent) diabetic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7497874" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414839" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A new equation to estimate glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10075613" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630928" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21059087" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Ability of cystatin C to detect acute changes in glomerular filtration rate provoked by hyperglycaemia in uncomplicated Type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482068" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Accuracy of GFR estimation in obese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30059756" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Accuracy of hematuria for predicting non-diabetic renal disease in patients with diabetes and kidney disease: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30286822" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hematuria and Renal Outcomes in Patients With Diabetic Chronic KidneyDisease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6829589" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Hematuria and red cell casts in typical diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29500121" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27693840" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Clinical predictors differentiating non-diabetic renal diseases from diabetic nephropathy in a large population of type 2 diabetes patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838100" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Renal pathological implications in type 2 diabetes mellitus patients with renal involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28878938" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Presentation, pathology and prognosis of renal disease in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27190327" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256393" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effect of a multifactorial intervention on mortality in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27531506" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25257325" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Diabetic kidney disease: a report from an ADA Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29520581" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Biomarkers of diabetic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209743" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16188894" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Role of inflammation in diabetic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29580582" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17113815" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22266664" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28476763" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30287518" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Association of Soluble TNFR-1 Concentrations with Long-Term Decline in Kidney Function: The Multi-Ethnic Study of Atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22266663" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25272234" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690958" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : CKD273, a new proteomics classifier assessing CKD and its prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27507891" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30455331" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : CKD273 Enables Efficient Prediction of Diabetic Nephropathy in Nonalbuminuric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30374033" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25063425" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Renal histologic changes and the outcome in patients with diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29180393" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Segmental Sclerosis and Extracapillary Hypercellularity Predict Diabetic ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23886566" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The modern spectrum of renal biopsy findings in patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28391311" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Should all patients with diabetes have a kidney biopsy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920336" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5031267" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Morphometric studies of the peripheral glomerular basement membrane in early juvenile diabetes. I. Development of initial basement membrane thickening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496194" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Diabetic nephropathy: Linking histology, cell biology, and genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498421" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : AJKD Atlas of Renal Pathology: diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34514200" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167701" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Pathologic classification of diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28340221" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469869" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Idiopathic nodular glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15056988" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Nodular glomerulosclerosis in cystic fibrosis mimics diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12203216" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
